

ACURA PHARMACEUTICALS, INC  
Form 8-K  
January 03, 2017

UNITED STATES

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D. C. 20549**

FORM 8-K

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act Of 1934**

**January 3, 2017**

Date of Report (Date of earliest event reported)

**ACURA PHARMACEUTICALS, INC.**

(Exact Name of Registrant as Specified in Charter)

**State of New York**

**1-10113**

**11-0853640**

(State of Other Jurisdiction of Incorporation) (Commission File Number) (I.R.S. Employer Identification Number)

616 N. North Court, Suite 120

Palatine, Illinois 60067

(Address of principal executive offices) (Zip Code)

**(847) 705-7709**

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 8.01 Other Events**

On January 3, 2017 we issued a press release announcing that we are exploring a range of financing and strategic alternatives, including a possible sale of the company and that we retained Roth Capital Partners LLC to assist in this process. A copy of our press release is attached as Exhibit 99.1 hereto and is incorporated by reference herein.

**Item 9.01 Financial Statements and Exhibits**

**Exhibit Number Description**

99.1 Press Release dated January 3, 2017

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

**ACURA  
PHARMACEUTICALS,  
INC.**

By: /s/ Peter A. Clemens  
Peter A. Clemens  
Senior Vice President  
& Chief Financial  
Officer

Date: January 3, 2017

**Exhibit Index**

**Exhibit Number Description**

99.1 Press Release dated January 3, 2017